Navigation Links
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
Date:9/17/2007

NEW HAVEN, Conn., Sept. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that an investigator-sponsored trial of its lead anti-cancer agent Cloretazine(R) (VNP40101M) in combination with Temodar(R) (temozolomide) in relapsed or progressive adult malignant gliomas had been initiated at the Robert H. Lurie Cancer Center under the direction of Dr. Jeffrey J. Raizer, Principal Investigator.

The objective of the trial is to establish the maximum tolerated dose (MTD) and safety profile of Cloretazine(R) (VNP40101M) in combination with temozolomide and then to study this dose in an expanded number of patients. Cohorts of 3-6 patients receive escalating doses of Cloretazine(R) (VNP40101M) until the MTD is determined (Phase I). In Phase II, response rates, progression-free survival and overall survival will be evaluated in addition to the safety profile. Patients receive oral temozolomide on days 1-7 and intravenous Cloretazine(R) (VNP40101M) over 15-30 minutes 2 hours after the last dose of temozolomide on day 7. Treatment repeats every 7 weeks in the absence of disease progression or unacceptable toxicity.

Correlative studies conducted as part of the trial will measure: (i) the level of O6 alkylguanine DNA alkyltransferase (AGT) expression in peripheral blood monocytes before treatment with temozolomide and just prior to the administration of Cloretazine(R) (VNP40101M); (ii) the status of O6- methylguanine-methyltransferase (MGMT) methylation as well as other methylation patterns in plasma from patients treated with this regimen relative to outcome; and (iii) Cloretazine(R) (VNP40101M) in the cerebral spinal fluid and serum/plasma in Phase II.

Dr. Raizer commented, "One
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
(Date:12/22/2014)... 2014 TWi Biotechnology, Inc., today announced ... AC-201, TWi Biotechnology,s lead drug candidate, from The ... for patent application numbered 201180018154.8.  This ... active metabolite for treatment of type II diabetes.  ... using AC-201 for type II diabetes, and provides ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that ... 1] , which will further reinforce the company,s commitment to ... world. "We are committed to adopting the Global ... culture and day-to-day operations of our company and through Astellas, ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... filed an Abbreviated New Drug Application (ANDA) with the ... market rivastigmine transdermal system patches, 4.6 mg/24 hr and ... a generic version of Novartis, Exelon(R) Patch. Exelon(R) is ...
Cached Medicine Technology:Astellas Signs United Nations Global Compact 2Astellas Signs United Nations Global Compact 3Watson Confirms Exelon(R) Patent Challenge 2Watson Confirms Exelon(R) Patent Challenge 3
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... York NY (PRWEB) December 22, 2014 ... that a federal panel of judges has granted a ... in the U.S. District Court, Eastern District of ... issued an order on December 12 to transfer over ... in 22 districts to the Louisiana court for consolidation ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... separated at the time of diagnosis do not live as ... the conclusion of a new study to be published in ... peer-reviewed journal of the American Cancer Society. The authors of ... with marital separation may compromise an individual,s immune system and ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Pulmonary Fibrosis is not much better than a death ... is less than three years. But researchers at ... a novel gene utilizing genetic and pharmacologic strategies was ... be developed for future testing in humans. The ...
... works best , SUNDAY, Aug. 23 (HealthDay News) -- Medics ... activity when trying to save a person who,s had a ... defibrillation to restart the heart. , But studies now show ... as ordinary cardiopulmonary resuscitation, or CPR. And what,s more, those ...
... ... facility, positioning the company to support defense-related semiconductor manufacturing and development programs. , ... Cherry Hill, NJ (PRWEB) ... Arms Regulations) registered for its Cherry Hill, New Jersey manufacturing facility. ITAR regulates the ...
... root, study finds , FRIDAY, Aug. 21 (HealthDay News) -- ... before they take root in the brain. , That,s the ... rats -- assuming the findings can be applied to humans, ... of Rio Grande do Sul, Brazil, with colleagues at the ...
Cached Medicine News:Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:New technique can help diagnose mesothelioma 2Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:It's Back to Basics to Save a Life 2Health News:It's Back to Basics to Save a Life 3Health News:International Micro Industries (IMI) is ITAR Registered 2Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: